Imlunestrant (LY3484356), developed by Loxo Oncology at Eli Lilly Corp., is a next-generation brain-penetrant, oral selective ERα degrader that exhibits potent activity in both ESR1 wild-type and mutant breast cancers (29, 60). The gene discussed is ESR1; the disease is breast carcinoma.